We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Between baseline and day 21, there was a –67% change in ...

Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn., Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (TRVI) (Nasdaq: TRVI), a clinical-stage biopharmaceutical company ...

Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy in ...

Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER study evaluating its investigational therapy Haduvio as a potential treatment ...

Camlipixant showed significant efficacy in patients with higher baseline cough frequency, despite not meeting the primary endpoint in the overall population. The trial demonstrated camlipixant's ...

Daily treatment with SC0023 yielded treatment efficacy 53.5% ± 19.2% relative to baseline in 24-hour daily cough rate and 19.5% ± 6.2% placebo effect Cough rate reduction was observed from the first ...

Topline results are expected in the first quarter of 2025 The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In ...